Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 8/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319333 | 0.80 | SIGMAR1 (0.40) | CXCR3OPRL1MEN1KMT2ADRD2 | |
| SCHEMBL4324383 | 0.79 | HSD11B1 (0.37) | CXCR3OPRL1HSD11B1CYP3A4 | |
| SCHEMBL4318605 | 0.73 | OPRL1 (0.35) | CXCR3OPRL1HSD11B1 | |
| SCHEMBL4323012 | 0.73 | DRD2 (0.39) | CXCR3OPRL1HSD11B1MEN1KMT2A | |
| SCHEMBL13914043 | 0.72 | SIGMAR1 (0.39) | HSD11B1 | |
| SCHEMBL4328886 | 0.71 | ALDH1A1 (0.36) | CXCR3OPRL1CYP3A4KDM4EALDH1A1 | |
| SCHEMBL4318372 | 0.71 | DRD2 (0.34) | OPRL1HSD11B1DRD2 | |
| SCHEMBL4325201 | 0.71 | ACHE (0.40) | MEN1KMT2AALDH1A1L3MBTL1DRD4 | |
| SCHEMBL4334661 | 0.70 | DRD2 (0.33) | OPRL1HSD11B1DRD2 | |
| SCHEMBL4329852 | 0.70 | DRD2 (0.33) | OPRL1HSD11B1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | CXCR3 1700/4885OPRL1 96/4885HSD11B1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.